Bas, so where does Sarepta stand now? Did they fail and are still pursuing for a FDA approval? SP dropped 40% to $63 on a bad news in Oct 2023; today at $98: a half recovered from the SP prior to the news. I don't get its CEO said: “met the standard" to show "evidence of effectiveness.” Maybe we can say that if Blarcamesine beats Acadia's drug for Rett?